Shigetoshi Fujiyama

Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

Haruhiko Yoshida, Yasushi Shiratori, Mitsuhiko Moriyama et al. · Annals of Internal Medicine · 1999 · 1.1K citations

Medicine, Oncology, Cancer Control +16

Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

Yasushi Shiratori, Fumio Imazeki, Mitsuhiko Moriyama et al. · Annals of Internal Medicine · 2000 · 737 citations · Full text

Medicine, Pathology, Hepatology +16

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker

Tetsuya Nakatsura, Yoshihiro Yoshitake, Satoru Senju et al. · Biochemical and Biophysical Research Communications · 2003 · 432 citations

Medicine, Cancer Biology, Oncology +14

Interferon therapy prolonged life expectancy among chronic hepatitis C patients

Haruhiko Yoshida, Yasuyuki Arakawa, Michio Sata et al. · Gastroenterology · 2002 · 236 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +14